STK-012

DRUG2 trials

Sponsors

Synthekine Inc., Synthekine

Conditions

1st Line NSCLCAdvanced Solid TumorNon Small Cell Lung CancerNon-small cell lung cancer (NSCLC)Untreated Advanced NSCLC

Phase 1

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

RecruitingNCT05098132

Synthekine1st Line NSCLC, Advanced Solid Tumor, Non Small Cell Lung Cancer +1

Start: 2022-01-25End: 2029-01-01Target: 364Updated: 2026-03-18

Phase 2

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications

Not yet recruitingCTIS2025-522632-14-00

Synthekine Inc.Non-small cell lung cancer (NSCLC)

Target: 56Updated: 2026-01-13

Related Papers

Abstract 6740: Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and chemotherapy in 1L PD-L1 negative non-squamous NSCLC

Cancer Research2026-04-03

Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)

Cancer Research2024-04-058 citations

Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)

Cancer Research2022-06-151 citations